Revvity (RVTY) to Post Quarterly Earnings on Tuesday

by · The Cerbat Gem

Revvity (NYSE:RVTY – Get Free Report) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $1.21 per share and revenue of $702.9570 million for the quarter. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 7:30 AM ET.

Revvity (NYSE:RVTY – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $711.12 million during the quarter, compared to analysts’ expectations of $704.07 million. Revvity had a return on equity of 8.00% and a net margin of 8.26%.Revvity’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $1.01 earnings per share. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Revvity Price Performance

NYSE:RVTY opened at $112.79 on Monday. Revvity has a 12-month low of $81.22 and a 12-month high of $118.30. The firm has a market capitalization of $12.58 billion, a price-to-earnings ratio of 53.96, a P/E/G ratio of 2.21 and a beta of 1.07. The stock’s 50 day moving average price is $106.51 and its two-hundred day moving average price is $99.88. The company has a quick ratio of 1.41, a current ratio of 1.72 and a debt-to-equity ratio of 0.37.

Analysts Set New Price Targets

A number of research firms recently weighed in on RVTY. Robert W. Baird set a $117.00 price target on Revvity in a research note on Wednesday, May 6th. Barclays upped their price objective on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Evercore reissued an “outperform” rating and issued a $125.00 price objective on shares of Revvity in a research report on Monday, July 6th. Sanford C. Bernstein initiated coverage on shares of Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 target price for the company. Finally, Stifel Nicolaus reduced their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a report on Wednesday, May 6th. Three analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $108.36.

Read Our Latest Stock Report on Revvity

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RVTY. CYBER HORNET ETFs LLC acquired a new stake in shares of Revvity during the second quarter worth $32,000. MUFG Securities EMEA plc acquired a new position in shares of Revvity in the second quarter valued at about $34,000. Headlands Technologies LLC bought a new position in Revvity during the second quarter worth about $49,000. Los Angeles Capital Management LLC bought a new position in Revvity during the fourth quarter worth about $51,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Revvity in the 4th quarter worth about $72,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Company Profile

(Get Free Report)

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

Featured Stories